Search clinical trials for: Durvalumab (Medi4736)

Total 763 results

Shanghai Chest Hospital
Wuhan University

Not yet recruiting

Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC (RELIEF)

Lung Cancer
Michael Hopp
AstraZeneca

Recruiting

Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)

Small Cell Lung Cancer Limited Stage

Germany
Association NVALT Studies

Recruiting

Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28) (NVALT28)

Carcinoma, Non-Small-Cell Lung

Netherlands
Western Sydney Local Health District
University of Western Sydney

Recruiting

Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.

Hepatitis | Lung Cancer, Non-small Cell | Lung Cancer Stage IV

Australia
University of Leeds
University College London Hospitals; The Leeds Teaching Hospitals NHS Trust; University... and other collaborators

Recruiting

A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC (CONCORDE)

Non Small Cell Lung Cancer

United Kingdom
National Cancer Institute (NCI)

Recruiting

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

EGFR-Mutated Non-Small-Cell Lung Carcinoma | Small Cell/Neuroendocrine

United States
Institut für Klinische Krebsforschung IKF GmbH...
Hannover Medical School; AstraZeneca

Recruiting

Durvalumab and Tremelimumab in Combination With Either Y-90 SIRT or DEB-TACE for Intermediate Stage HCC

HCC | Hepatocellular Carcinoma Non-resectable

Germany
Fudan University

Not yet recruiting

The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)

Hepatocellular Carcinoma
Georgetown University
AstraZeneca

Recruiting

Durvalumab and Tremelimumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer

Carcinoma, Non-Small Cell Lung

United States
National Cancer Center Hospital East
AstraZeneca; Japan Agency for Medical Research and Development; Japan Clinical...

Not yet recruiting

Efficacy and Safety of CRT, Durvalumab and Surgery for SST (DEEP_OCEAN)

Non Small Cell Lung Cancer Stage III | Superior Sulcus Tumor | Non-small Cell Lung Cancer Stage IIB
Washington University School of Medicine
AstraZeneca

Recruiting

Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma

Primary Central Nervous System Lymphoma

United States
RenJi Hospital

Recruiting

Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 ) (Dulect2020-1)

Liver Transplant; Complications | Liver Carcinoma

China
Maastricht Radiation Oncology

Recruiting

Immune Profiling of Stage III Non-small Cell Lung Cancer Patients Treated With Concurrent Chemoradiation and Adjuvant Durvalumab: A Prospective Observational Phase II Trial (IPON-1)

Carcinoma, Non-Small-Cell Lung

Netherlands
Loren Mell, MD

Recruiting

QUantitative Assessment of Swallowing After Radiation (QUASAR) (QUASAR)

Head and Neck Cancer | Dysphagia | Oropharyngeal Dysphagia | Oropharynx Cancer | Oropharynx Squamous Cell Carcinoma

United States
Hui Bu

Not yet recruiting

Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

Leptomeningeal Metastasis | Durvalumab
Institut für Klinische Krebsforschung IKF GmbH...
AstraZeneca; Thoraxklinik-Heidelberg gGmbH

Recruiting

Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy (TRADE-hypo)

NSCLC, Stage III

Germany
Seoul National University Hospital

Recruiting

AZD6738 Plus Durvalumab in Biliary Tract Cancer

Bile Duct Cancer | Chemotherapy Effect

Korea, Republic of
National Taiwan University Hospital
AstraZeneca; Ministry of Science and Technology, Taiwan, ROC

Recruiting

Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection

Advanced Hepatocellular Carcinoma

Taiwan
Zhejiang Cancer Hospital

Not yet recruiting

Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung
Swiss Group for Clinical Cancer Research

Recruiting

Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

NSCLC | Non-small Cell Lung Cancer

Switzerland
Asan Medical Center

Recruiting

Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Korea, Republic of
University Hospital, Essen

Recruiting

Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC. (ESPADURVA)

NSCLC, Stage III

Germany
CCTU- Cancer Theme
Microbiotica Ltd

Recruiting

Microbiome Immunotherapy Toxicity and Response Evaluation

Melanoma | Lung Cancer | Renal Cancer

United Kingdom
Masonic Cancer Center, University of Minnesota

Recruiting

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Lung Cancer | Adenocarcinoma of Lung

United States
AUSL Romagna Rimini
AstraZeneca; Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Recruiting

Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer (PANDORA)

RECTAL CANCER

Italy
AstraZeneca

Recruiting

Open Label, Multicenter, Real World Practice of Durvalumab in Lung Cancer (Imfinzi PMS) (Imfinzi PMS)

Lung Cancer

Korea, Republic of
MedPacto, Inc.
AstraZeneca

Not yet recruiting

Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

Urothelial Carcinoma Recurrent | Advanced Urothelial Carcinoma

United States
University Health Network, Toronto

Recruiting

Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors (SOLID)

Glioma | Solid Tumor | Cholangiocarcinoma | IDH Mutation

Canada
National Cancer Institute, Naples
AstraZeneca; University of Campania "Luigi Vanvitelli"

Recruiting

A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) (MILES-5)

Carcinoma, Non-Small-Cell Lung

Italy
ETOP IBCSG Partners Foundation
AstraZeneca

Recruiting

Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC (CHESS)

Non-small Cell Lung Cancer | Oligometastasis | Stage IV

Switzerland, Netherlands, Spain, Italy
National Cancer Institute (NCI)

Recruiting

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

Hepatocellular Carcinoma | Hepatocellular Cancer | Metastatic Hepatocellular Carcinoma

United States
Humanity & Health Medical Group Limited

Recruiting

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

Hepatocellular Carcinoma

Hong Kong
Canadian Cancer Trials Group
AstraZeneca

Recruiting

A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

Cancer

Canada
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Recruiting

hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study" (ARCADIA)

Bladder Carcinoma

Italy
UNICANCER

Recruiting

Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer (ARION)

Esophagus Cancer | Unresectable Malignant Neoplasm

France
National University Hospital, Singapore

Recruiting

Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies (MEDIPAC)

Solid Tumor, Adult

Singapore
Institute of Cancer Research, United Kingdom
AstraZeneca

Recruiting

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer (PHOENIX)

Breast Neoplasm

United Kingdom
Yonsei University
Samsung Medical Center; AstraZeneca; Seoul National University Hospital; Korean... and other collaborators

Recruiting

An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)

Platinum-resistant Recurrent Ovarian Cancer

Korea, Republic of
Noah Hahn, M.D.
AstraZeneca; Hoosier Cancer Research Network

Recruiting

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder (ADAPT-BLADDER)

Bladder Cancer | Urothelial Carcinoma

United States
University College, London
AstraZeneca; Cancer Research UK; Kidney Cancer UK

Recruiting

Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART)

Renal Cell Carcinoma

United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

Recurrent Adult Lymphoblastic Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent... and other conditions

United States
Azienda Ospedaliero-Universitaria Careggi

Not yet recruiting

Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer (DUCRO-HN)

Head and Neck Neoplasms
AstraZeneca

Recruiting

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer

Spain, United States, Belgium, United Kingdom, France, Hungary, Canada, Korea, Republic of, Australia
Centre Leon Berard
National Cancer Institute, France

Recruiting

Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (MOST plus)

Malignant Solid Neoplasms

France
QuantumLeap Healthcare Collaborative

Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)

Breast Cancer | Breast Neoplasms | Breast Tumors | HER2-positive Breast Cancer | Angiosarcoma | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer

United States
AstraZeneca

Completed

Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA)

Carcinoma, Non-Small-Cell Lung

Taiwan
AstraZeneca
The Gynecologic Oncology Group (GOG) Foundation Inc; The European Network for...

Active, not recruiting

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E)

Endometrial Neoplasms

United States, Belgium, Canada, Germany, Korea, Republic of, Brazil, Hungary, Japan, Poland, Russian Federation, China, Hong Kong, Spain, Israel, Australia, India, Singapore, Greece, Estonia, Lithuania, Mexico, Colombia
Centre hospitalier de l'Université de Montréal...
AstraZeneca

Active, not recruiting

Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas

Head and Neck Squamous Cell Carcinoma | Metastatic Squamous Cell Carcinoma

Canada
UNC Lineberger Comprehensive Cancer Center
AstraZeneca

Active, not recruiting

Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

Oral Cancer | Larynx | Lip | Digestive Organs--Diseases

United States
Weill Medical College of Cornell University

Completed

A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer

Small-cell Lung Cancer

United States

Search clinical trials for: Durvalumab (Medi4736)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations